Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

TIDES: Oligonucleotide & Peptide Therapeutics Content Hub
Menu

Jesper Lau, PhD
Vice President, Protein and Peptide Chemistry at Novo Nordisk A/S
Speaker

Agenda Sessions

  • Discovery and Development of Semaglutide – The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes

    On Demand - For Members
    View Session

At this event

Prev
Next
Marc Abrams, PhD
Vice President, Discovery Research
Dicerna Pharmaceuticals

See Jesper at TIDES: Oligonucleotide & Peptide Therapeutics Content Hub